This annual shot might protect against HIV infections
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Once-a-year shot for HIV protection passes early safety trial
An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research published in The Lancet medical journal. The drug lenacapavir passed a critical Phase I testing trial and now may become a highly-effective and convenient form of HIV prevention.
Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success
Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) following the success of a Phase I study. The Phase I trial investigated two single 5,
Gilead presents data for once-yearly lenacapavir for HIV prevention
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of
Annual jab for HIV protection passes trial hurdle
If future trials go well - now it has passed the first, Phase I, testing hurdle - it could become the longest-acting form of HIV prevention available. Currently, people can take daily pills or sometimes have injections every eight weeks,
Healio3d
Two more people potentially cured of HIV
Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...
HIV's latent reservoir: New insights into Nef protein offer potential strategy to improve treatment
A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...
Managed Healthcare Executive16h
If Twice-Yearly Lenacapavir Could Be a HIV PrEP Game Changer, Would a Once-Yearly Version Be a HIV Epidemic Ender?
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
allAfrica.com on MSN2d
US funding cuts imperil search for HIV vaccine
A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...
“Magic” for Those Who Can’t Take Pills: Groundbreaking HIV Treatment Achieves 98% Viral Suppression
UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...
Applied Clinical Trials Online1d
Phase I Trial Supports Development of Once-Yearly Lenacapavir as Long-Acting HIV PrEP Option
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
Fierce Biotech3d
Immunocore T-cell engager clears safety hurdle, reduces HIV reservoir in some patients
Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...